Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK Study of PF-06946860 (Ponsegromab) in Healthy Adults
NCT03599063Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jul 2018
- Primary completion
- Sep 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ponsegromab in cancer cachexia (8 cohorts), sponsored by Pfizer. Primary endpoint: Incidence of participants experiencing Adverse Events (AE). Started Jul 2018; status: completed.
02
Drugs
ponsegromab
03
Conditions
cancer cachexia
Beyond the preview
Go deeper on NCT03599063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03599063.